Peggy Wallace
Adult Health · Tampa, FLNPI 1285930123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 427 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Viiv Healthcare Company at 37.1% of the total. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $27.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$3K
- Theratechnologies Inc.$2K
- Merck$928
- Johnson & Johnson$719
- Napo Pharmaceuticals Inc$242
- plus $770 from 10 others
Across 9 payments — averaging $142.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$240%
- Food & beverage$11,42899%
- Education$1291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 166 | $4,291 |
| Gilead | 90 | $2,670 |
| Theratechnologies Inc. | 52 | $1,960 |
| Merck | 44 | $928 |
| Johnson & Johnson | 39 | $719 |
| Napo Pharmaceuticals Inc | 7 | $242 |
| Janssen Scientific Affairs, LLC | 9 | $156 |
| EMD Serono, Inc. | 4 | $155 |
| Janssen Products, LP | 2 | $129 |
| AbbVie | 2 | $116 |
| Paratek Pharmaceuticals, Inc. | 6 | $109 |
| Lilly USA, LLC | 2 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Phadia US Inc. | 1 | $14 |
| Qiagen, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,580 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 201 | $769,553 |
| JulucaDolutegravir/Rilpivirine | 128 | $443,546 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 113 | $419,327 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 101 | $408,123 |
| TivicayDolutegravir Sodium | 101 | $221,996 |
| DescovyEmtricitabine/Tenofov Alafenam | 102 | $217,844 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 33 | $166,996 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 36 | $141,939 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $87,064 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $67,512 |
| Darunavir | 41 | $47,577 |
| MounjaroTirzepatide | 27 | $33,201 |
| PifeltroDoravirine | 12 | $20,763 |
| EvotazAtazanavir Sulfate/Cobicistat | 13 | $19,619 |
| EdurantRilpivirine Hcl | 13 | $18,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $2,670 | $1,395,520404 claims |
| Viiv Healthcare CompanyJuluca, Tivicay, Triumeq, Cabenuva, Dovato | $4,291 | $962,057301 claims |
| Janssen Products, LPSymtuza | $129 | $166,99633 claims |
| Lilly USA, LLCMounjaro | $28 | $33,20127 claims |
| MerckPifeltro, Januvia | $928 | $28,25925 claims |
| Janssen Scientific Affairs, LLCEdurant | $156 | $18,66013 claims |
| Boehringer IngelheimCombivent Respimat | $26 | $10,77922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Tampa
- Jamie JohnsonTampa$58K
- Jennifer GodshallTampa$29K
- Michael RoggelinTampa$21K
- Mercedes FernandezTampa$19K
- Cashawna SchlossnagleTampa$18K
- Jennifer BishopTampa$17K
- Meredith ButlerTampa$16K
- Kimberly RandolphTampa$14K
- Esmeralda YoungTampa$14K
- Sarah KossiverTampa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.